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ABSTRACT 
In this article, we review on the current concepts about Nesfatin-1 as a new anti-obesity 
treatment and evaluate the existing issues in the context of this knowledge and the available 
literature. The intent is to enable clinicians to know Nesfatin-1 as a new anti-obesity treatment 
and make rational decisions based on this perspective as possible clinical application. Future 
research should seek to clarify whether Nesfatin-1 would be beneficial in the management of 
obesity. 
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INTRODUCTION 
Nesfatin-1 is an 82-amino-acid peptide 
originated from post translational processing 
of the N-terminal fragment of nucleobindin 2 
(NUCB2), a 396-amino-acid protein excep-
tionally conserved across mammalian spe-
cies (Oh-I et al., 2006). Post translational 
cleavage of NUCB-2 appears in the expres-
sion of nesfatin-2 fragment (85–163) and 
nesfatin-3 fragment (166–396) in addition to 
nesfatin-1 (Oh-I et al., 2006). Oh-I et al. 
(2006) suggested that nesfatin-1 (named as 
acronym for NEFA/nucleobindin2-encoded 
satiety- and fat-influencing protein) may 
have physiological importance in regulating 
food intake. 
In fact, nesfatin-1 injected into the third 
brain ventricle reduces food consumption 
occurring during the dark phase, whereas 
nesfatin-2 or nesfatin-3 had no effect (Oh-I 
et al., 2006). In the same way, continuous in-
fusion of nesfatin-1 (5 pmol/day for 10 days 
into the third brain ventricle) decreases sig-
nificantly food intake and body weight gain 
in rats (Oh-I et al., 2006). Conversely, third 
ventricle infusion of a NUCB-2 antisense ol-
igonucleotide increases food intake and body 
weight gain compared with a missense 
NUCB-2 oligonucleotide (Oh-I et al., 2006). 
Additionally, a 24-h fast decreased the ex-
pression of NUCB-2 in the paraventricular 
nucleus (PVN) (Oh-I et al., 2006).  
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Some studies (Oh-I et al., 2006; Zheng et 
al., 2009; Ishida et al., 2012; Albayrak et al., 
2013) showed high expression level of 
nesfatin-1/NUCB-2 expression in relevant 
hypothalamic and medullary sites implicated 
in feeding regulation in rats. The arcuate nu-
cleus, PVN, and the nucleus of the solitary 
tract (NTS), further supporting the evidence 
that nesfatin-1 is involved in food intake 
regulation.  
Nesfatin-1 is co-expressed with Melanin-
Concentrating Hormone (MCH) in neurons 
from the tuberal hypothalamic area (THA) 
which are recruited during sleep states, espe-
cially paradoxical sleep (PS) (Jego et al., 
2012). To help decipher the contribution of 
this contingent of THA neurons to sleep reg-
ulatory mechanisms, Jego et al. (2012) thus 
investigated in rats whether the co-factor 
Nesfatin-1 is also endowed with sleep-
modulating properties. It was found that the 
disruption of the brain Nesfatin-1 signaling 
achieved by icv administration of Nesfatin-1 
antiserum or antisense against the nucle-
obindin2 (NUCB2) prohormone suppressed 
PS with little, if any alteration of slow wave 
sleep (SWS) (Jego et al., 2012). Additional-
ly, the infusion of Nesfatin-1 antiserum after 
a selective PS deprivation, designed for ele-
vating PS needs, severely prevented the en-
suing expected PS recovery (Jego et al., 
2012). Strengthening these pharmacological 
data, Jego et al. (2012) finally demonstrated 
by using c-Fos as an index of neuronal acti-
vation that the recruitment of Nesfatin-1-
immunoreactive neurons within THA is 
positively correlated to PS but not to SWS 
amounts experienced by rats prior to sacri-
fice. In conclusion, this work supports a 
functional contribution of the Nesfatin-1 sig-
naling, operated by THA neurons, to PS reg-
ulatory mechanisms. Jego et al. (2012) pro-
posed that these neurons, likely releasing 
MCH as a synergistic factor, constitute an 
appropriate lever by which the hypothalamus 
may integrate endogenous signals to adapt 
the ultradian rhythm and maintenance of PS 
in a manner dictated by homeostatic needs. 
This could be done through the inhibition of 
downstream targets comprised primarily of 
the local hypothalamic wake-active orexin- 
and histamine-containing neurons (Jego et 
al., 2012). 
Activation of brain CRF signaling path-
ways by CRF acting on CRF1 and CRF2 re-
ceptors and by selective endogenous CRF2 
agonists urocortin 2 or 3 (Chen et al., 2013) 
inhibits food intake (Doyon et al., 2004). 
Nesfatin-1 injected intracerebroventricularly 
significantly decreased gastric emptying 
(García-Galiano et al., 2012). Goebel-Sten-
gel and Wang (2012) showed that NUCB2/ 
nesfatin-1 immunoreactivity is distributed in 
mouse brain areas involved in the regulation 
of stress response and visceral functions ac-
tivated by an acute psychological stressor 
suggesting that nesfatin-1 might play a role 
in the efferent component of the stress re-
sponse. 
 
NESFATIN-1/NUCB-2 AND  
ANOREXIGENIC EFFECT  
Peptides regulating food intake often act 
in concert or in series with other neuro-
transmitters to exert their actions (Perry and 
Wang, 2012). Nesfatin-1/NUCB-2 is co-
localized with a number of hypothalamic 
peptides regulating food intake (Fort et al., 
2008; Shimizu et al., 2009b; Maejima et al., 
2009; Yoshida et al., 2010; Tan et al., 2011; 
Kerbel and Unniappan, 2012; Goebel-
Stengel and Wang, 2013). Several interac-
tions have been described to underlie the 
central anorexic effect of nesfatin-1 (Shimizu 
et al., 2009c). It has also been shown to play 
important roles in the control of cardiovascu-
lar function (Mimee et al., 2012). In situ hy-
bridization and immunohistochemical re-
searches have evidentiated the expression of 
nesfatin-1 throughout the brain and, particu-
larly, in the medullary autonomic gateway 
known as the nucleus of the solitary tract 
(NTS) (Mimee et al., 2012). Mimee et al. 
(2012) showed that provide critical insight 
into the circuitry and physiology involved in 
the profound effects of nesfatin-1 and high-
light the NTS as a key structure mediating 
these autonomic actions. 
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Two proteins have been localized in the 
arcuate nucleus (ARC) and implicated in the 
regulation of food intake: the serine-
threonine-kinase mammalian target of ra-
pamycin (mTOR) as part of the TOR signal-
ing complex 1 (TORC1), and nesfatin-1 de-
rived from the precursor protein nucle-
obindin2, as reported by Inhoff et al. (2010). 
In fact, nesfatin-1 is not only intracellularly 
co-localized with cocaine- and ampheta-
mine-regulated transcript (CART) peptide as 
reported before, but also with phospho-
mTOR (pmTOR) and neuropeptide Y (NPY) 
in ARC neurons (Inhoff et al., 2010). This 
data could also confirm results from previous 
studies, showing that the majority of nesfat-
in-1 neurons are also positive for CART pep-
tide, whereas most of the pmTOR is co-
localized with NPY and only to a lesser ex-
tent with CART (Inhoff et al., 2010).  
A study, described by Maejima et al. 
(2009), provided a strong evidence for the 
involvement of oxytocin pathway in nesfat-
in-1’s inhibitory effect on food intake. First 
of all, oxytocin injected into the 3v reduces 
food intake via a leptin-independent mecha-
nism (Maejima et al., 2009). At the same 
time nesfatin-1 injected into the 3v activates 
oxytocin-positive neurons in the magnocellu-
lar part of the PVN as assessed by double la-
belling for Fos/oxytocin immunoreactivity 
and in vitro it stimulates the release of oxy-
tocin from PVN neurons (Maejima et al., 
2009). In addition there is pharmacologic 
and anatomical support for oxytocinergic 
projections from the PVN to the nucleus of 
the solitary tract to be involved in the ano-
rexigenic signalling of nesfatin-1 (Maejima 
et al., 2009). An oxytocin receptor antagonist 
injected into the hindbrain at the level of the 
4v blocked the food intake reducing effect of 
nesfatin-1 injected into the PVN and tracing 
studies showed synaptic contacts between 
oxytocinergic nerve terminals and pro-
opiomelanocortin (POMC) neurons in the 
nucleus of the solitary tract. Yosten and 
Samson (2010) also showed that an oxytocin 
antagonist injected intracerebroventricular 
blocks the food intake suppressing effects of 
intracerebroventricular nesfatin-1 and α-
melanocyte-stimulating hormone (α-MSH). 
Therefore, nesfatin-1 acts through a serial 
neuronal circuit, in which nesfatin-1 acti-
vates the central melanocortin system, 
which, in turn, acts through the central oxy-
tocin system, leading to an inhibition of food 
and water intake and an increase in mean ar-
terial pressure (Yosten and Samson, 2010). 
Future research should seek to clarify 
whether the hypothalamic/nesfatin-1-oxyto-
cin-brainstem/POMC signalling is the pre-
dominant pathway or an intrahypothalamic 
nesfatin-1-POMC/oxytocin network exists. 
Some studies showed that based on the 
observation of a delayed and long lasting an-
orexigenic effect, following intracerebroven-
tricular injection of nesfatin-1 which mimics 
the characteristics of the food intake reduc-
ing effect of CRF2 receptor agonists, uro-
cortins (Chen et al., 2013; Yakabi et al., 
2011). The possible involvement of the 
CRF2 receptors in the mediation of nesfatin-
1’s effect was investigated. The CRF2 an-
tagonist, astressin2-B (Wang et al., 2013), 
injected intracerebroventricular completely 
abolished the dark phase food intake reduc-
tion induced by intracerebroventricular 
nesfatin-1 (Stengel et al., 2009). By contrast, 
a control peptide of similar structure as 
astressin2-B but without affinity to the CRF2 
receptor did not influence intracerebroven-
tricular nesfatin-1’s action (Stengel et al., 
2009). However as reported by Stengel et al. 
(2009), astressin2-B injected intracerebro-
ventricular did not modulate the rapid onset 
reduction of food intake observed after in-
tracerebroventricular injection of nesfatin-1. 
In contrast to the effect on food intake, the 
CRF2 antagonist, astressin2-B injected in-
tracerebroventricular did not alter the intrac-
erebroventricular nesfatin-1 induced delayed 
gastric emptying (Stengel et al., 2009) giving 
rise to different downstream signalling 
pathways mediating intracerebroventricular 
nesfatin-1’s inhibitory effects on food intake 
and gastric transit. Finally, as reported by 
Yosten and Samson (2010), the melanocortin 
3/4 receptor antagonist, SHU9119 injected 
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intracerebroventricular diminished, and into 
the 3v abolished (Oh-I et al., 2006), the ano-
rexigenic effect of nesfatin-1. Nesfatin-1 
probably act in series through the recruit-
ment of the central melanocortin and CRF2's 
pathways to reduce food intake. 
Another, intracerebroventricular admin-
istration of nesfatin-1 induced c-Fos expres-
sion in CRF neurons, and nesfatin-1 in-
creased cytosolic Ca2+ concentrations in 
single CRF neurons in the PVN (Jia et al., 
2013). It is now well established that the 
brain CRF/CRF1 signaling system modulates 
pain responses (Jia et al., 2013). These ob-
servations suggest that nesfatin-1 may be in-
volved in the autonomic regulation of viscer-
al sensation (Jia et al., 2013). Jia et al. (2013) 
suggested that nesfatin-1 may be associated 
with the visceral hypersensitivity state of ir-
ritable bowel syndrome, and this may be 
mediated, at least in part, by brain 
CRF/CRF1 signaling pathways. 
 
NESFATIN-1 AND ANTI-OBESITY 
TREATMENT  
It has also been postulated that nesfatin-
1/NUCB-2 may be produced by the hypo-
thalamus (Goebel-Stengel and Wang, 2013); 
the relatively high CerebroSpinalFluid 
(CSF)/plasma nesfatin-1/NUCB-2 ratios 
suggest that a substantial amount of CSF 
nesfatin-1/NUCB-2 may originate from cen-
tral neurons. The possible discrepancy in the 
production of nesfatin-1/NUCB-2, by these 
central neurons may account for the differ-
ences in CSF/plasma nesfatin-1/NUCB-2 ra-
tio between obese and lean subjects observed 
by Tan et al. (2011). Furthermore, it is prob-
able that nesfatin-1/NUCB-2 has protein 
binding, and that differences in protein bind-
ing in obese and lean subjects may also ex-
plain these findings. Finally, it is possible 
that the efficiency of nesfatin-1/NUCB-2 up-
take into CSF is reduced in obese individu-
als, possibly due to saturation of transporters 
(Tan et al., 2011). Further studies could be 
useful to elucidate this hypothesis. Some da-
ta demonstrated that nesfatin-1/NUCB-2 is a 
novel depot-specific adipokine preferentially 
expressed in subcutaneous adipose tis-
sue/adipocytes. Adipose tissue nesfatin-
1/NUCB-2 expression increases with obesity 
and is altered in states of feeding and malnu-
trition (Ramanjaneya et al., 2010). 
Reduced leptin sensitivity or leptin re-
sistance is a common phenomenon in obesity 
(Ramanjaneya et al., 2010). In the light of 
this and the pre-clinical findings that central 
and peripheral injection of nesfatin-1 exerts 
its food reducing effects via a leptin-
independent mechanism (Oh-I et al., 2006; 
Shimizu et al., 2009a), targeting nesfatin-1 
may be a promising approach in the drug 
treatment of obesity and its complications. 
Ongoing pre-clinical data suggest the possi-
ble use of subcutaneous and intranasal routes 
of nesfatin-1 administration (Shimizu et al., 
2009c), which needs to be further explored. 
Another important aspect to be unraveled is 
the weight loss upon chronic administration 
of nesfatin-1 (Li et al., 2010; Gonzalez et al., 
2012; Li et al., 2013; Dong et al., 2013) and 
possible related changes in energy balance 
and/or basal metabolic rate (Foo et al., 2008; 
García-Galiano et al., 2010; Gonzales et al., 
2011; Pałasz et al., 2012; Kerbel and Un-
niappan, 2012; García-Galiano et al., 2012; 
Ghanbari Niaki et al., 2013; Vas et al., 2013) 
for which studies so far are limited. In fact, 
nesfatin-1 has a remarkably prolonged effect 
on food intake and body temperature 
(Könczöl et al., 2012). Time course of 
nesfatin-1's effects may be varied depending 
on the time applied (Könczöl et al., 2012). 
Many of the nesfatin-1/NUCB2 neurones are 
cold sensitive, and are positioned in key cen-
tres of thermoregulation (Könczöl et al., 
2012). Nesfatin-1 regulates energy expendi-
ture a far more potent way than it was recog-
nised before making it a preferable candidate 
anti-obesity drug (Könczöl et al., 2012).  
Future research should seek to clarify 
whether nesfatin-1/NUCB-2 would be bene-
ficial in the management of obesity. Another, 
bariatric surgery produces differential influ-
ences with regards to circulating nesfatin-1 
and in particular the receptor involved in the 
peptide's actions, and the processing of 
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NUCB2 to nesfatin-1 in hypotalamic or gut 
tissues still remain elusive (Finelli et al., 
2014). 
 
CONCLUSIVE REMARKS 
The data obtained in basic experiments 
of nesfatin-1 should be useful for the devel-
opment of a new anti-obesity treatment. 
However, the mechanisms of endocrine and 
metabolic effects of nesfatin-1 have not been 
known well by now, and the influences of 
nesfatin-1 administered peripherally should 
be much more clarified in vivo before starting 
controlled clinical trials in the future. In fact, 
the details of nesfatin-1 physiology ought to be 
clarified, and it may be considered suitable in 
the future, as a potential drug in the pharma-
cotherapy of obesity. On the other hand, some 
putative nesfatin-1 antagonists may improve 
eating disorders (Pałasz et al., 2012) 
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